<DOC>
	<DOC>NCT01215942</DOC>
	<brief_summary>The primary purpose of this study is to help answer if LY2127399 is safe and effective during long-term treatment in patients with Rheumatoid Arthritis. This study is comprised of 2 periods: Period 1 - unblinded treatment for up to 240 weeks for patients who enroll from Study H9B-MC-BCDO (BCDO) (NCT01202760) or Study H9B-MC-BCDV (BCDV) (NCT01202773) or up to 168 weeks for patients who enroll from Study H9B-MC-BCDM (BCDM) (NCT01198002). Period 2 - 48 week post treatment follow up</brief_summary>
	<brief_title>An Open Label Study for Patients With Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>Completion of 24 weeks of participation in Study H9BMCBCDO or Study H9BMCBCDV, or have completed 100 weeks of participation in Study H9BMCBCDM Woman must not be pregnant, breastfeeding, or become pregnant during the study Current symptoms of a serious disorder or illness</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>Rheumatoid Arthritis</keyword>
</DOC>